We reviewed the existing literature comparing TC and anthracycline-taxane-containing chemotherapy regimens in patients with stages I–III HER2-negative breast cancer to investigate and compare their impact on DFS, OS and cardiotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.